China Approves CanSinoBIO's mRNA COVID-19 Vaccine for Clinical Trials
CanSino Biologics Inc. (CanSinoBIO) has received approval from China's medical products regulator to begin clinical trials for its mRNA COVID-19 vaccine candidate.
© Copyright 2025. All Rights Reserved by MedPath